Morgan Stanley Beyond Spring Inc. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Beyond Spring Inc. stock. As of the latest transaction made, Morgan Stanley holds 8,199 shares of BYSI stock, worth $19,677. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,199

Previous 9,110 10.0%

Holding current value

$19,677

Previous $8,000 262.5%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.85 - $3.63 $774 - $3,306	-911 Reduced 10.0%	8,199 $29,000
Q4 2023 Feb 13, 2024	SELL	$0.67 - $1.12 $2,010 - $3,360	-3,000 Reduced 24.77%	9,110 $8,000
Q2 2023 Aug 14, 2023	BUY	$0.89 - $1.39 $178 - $278	200 Added 1.68%	12,110 $14,000
Q1 2023 May 15, 2023	SELL	$1.06 - $3.05 $983 - $2,830	-928 Reduced 7.23%	11,910 $13,000
Q4 2022 Feb 14, 2023	SELL	$0.56 - $2.61 $61,658 - $287,374	-110,105 Reduced 89.56%	12,838 $24,000

Q3 2022 Nov 14, 2022	SELL	$1.06 - $1.81 $318,200 - $543,342	-300,189 Reduced 70.94%	122,943 $122,000
Q2 2022 Oct 27, 2022	SELL	$1.13 - $2.66 $490,799 - $1.16 Million	-434,336 Reduced 50.65%	423,132 $609,000
Q2 2022 Aug 15, 2022	SELL	$1.13 - $2.66 $490,799 - $1.16 Million	-434,336 Reduced 50.65%	423,132 $609,000
Q1 2022 Oct 27, 2022	BUY	$1.68 - $5.01 $729,684 - $2.18 Million	434,336 Added 102.65%	857,468 $1.89 Million
Q1 2022 May 13, 2022	BUY	$1.68 - $5.01 $140,748 - $419,732	83,779 Added 10.83%	857,468 $1.89 Million
Q4 2021 Feb 14, 2022	BUY	$4.02 - $16.84 $1.29 Million - $5.39 Million	319,883 Added 70.49%	773,689 $3.51 Million
Q3 2021 Nov 15, 2021	BUY	$9.26 - $31.31 $4.2 Million - $14.2 Million	453,806 New	453,806 $7.15 Million

Others Institutions Holding BYSI

# of Institutions

Shares Held

5.44M

Call Options Held

30.3K

Put Options Held

1.8K

View Full List

About BeyondSpring Inc.

Ticker BYSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,928,900
Market Cap $93.4M
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...

More about BYSI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account